- Home
- NRIX vs NMM Comparison
NRIX vs NMM Comparison
Compare NRIX & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- NMM
- Stock Information
- Founded
- NRIX 2009
- NMM 2007
- Country
- NRIX United States
- NMM Greece
- Employees
- NRIX N/A
- NMM N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- NMM Marine Transportation
- Sector
- NRIX Health Care
- NMM Consumer Discretionary
- Exchange
- NRIX Nasdaq
- NMM Nasdaq
- Market Cap
- NRIX 1.1B
- NMM 959.8M
- IPO Year
- NRIX 2020
- NMM 2007
- Fundamental
- Price
- NRIX $9.50
- NMM $36.96
- Analyst Decision
- NRIX Strong Buy
- NMM Strong Buy
- Analyst Count
- NRIX 17
- NMM 1
- Target Price
- NRIX $30.71
- NMM $80.00
- AVG Volume (30 Days)
- NRIX 942.9K
- NMM 105.6K
- Earning Date
- NRIX 04-08-2025
- NMM 05-07-2025
- Dividend Yield
- NRIX N/A
- NMM 0.54%
- EPS Growth
- NRIX N/A
- NMM N/A
- EPS
- NRIX N/A
- NMM 11.07
- Revenue
- NRIX $56,417,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- NRIX $15.73
- NMM N/A
- Revenue Next Year
- NRIX N/A
- NMM $6.96
- P/E Ratio
- NRIX N/A
- NMM $3.33
- Revenue Growth
- NRIX N/A
- NMM 0.28
- 52 Week Low
- NRIX $8.18
- NMM $28.37
- 52 Week High
- NRIX $29.56
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- NRIX 35.33
- NMM 59.81
- Support Level
- NRIX $9.02
- NMM $35.03
- Resistance Level
- NRIX $11.56
- NMM $37.40
- Average True Range (ATR)
- NRIX 0.61
- NMM 1.18
- MACD
- NRIX -0.07
- NMM 0.63
- Stochastic Oscillator
- NRIX 14.29
- NMM 92.21
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.